{
    "paper_id": "3da5ec0ed1ebc81a80a9b717d69d06d72a496df1",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": ". The storage of COVID-19 vaccines is important from the standpoint of preserving vaccine immunogenicity and efficacy as well as preparing healthcare workers who will be receiving and administering the vaccines (5). The complete, intact mRNA molecule is essential to its potency as a vaccine as a small degradation reaction, anywhere along a mRNA strand, can negatively impact the translation of that strand leading to incomplete expression of the target antigen (6). Following approval by regulatory authorities, mRNA vaccine doses will have to be manufactured, shipped across many cities as well as countries, stored at end-user sites, and subsequently utilized for large-scale vaccination (6). Pfizer's mRNA vaccine has to be stored in a \u00c070 Celsius (\u00c094 degrees F) ultra-cold freezer (5) . The efficacy of the vaccine can decrease if it not stored at a precise temperature (7) . Furthermore, lasting immunity potential and long-term side effects of the vaccine are not known (7) . Time will tell if vaccine-elicited neutralization antibody levels are adequate for preventing or ameliorating COVID-19 disease progression (1) . Lack of knowledge about lasting immunity may complicate the capacity of healthcare providers to plan vaccine timing, dosing, and budgeting (7) . Furthermore, the World Trade Organization was asked to waive some provisions in the international agreements that control intellectual property rights with the aim of accelerating efforts to control the COVID-19 pandemic and ensure that developing countries are not left behind (8) due to financial limitations. Another ear of concern is the possibility of patients and healthcare workers suffering from needle stick injuries because of COVID-19 vaccination campaigns. Sharp injury can occur due to recapping, mishandling, passing of sharps or leaving the sharps on surfaces (9) . Training can assist in alleviating these problems with the newly approved mRNA vaccine injections. A research group has also suggested the use of microneedles for one of the vaccine candidates in development (10) . The use of microneedles can reduce some of the problems encountered with hypodermic needles (11) .",
            "cite_spans": [
                {
                    "start": 788,
                    "end": 791,
                    "text": "(5)",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 877,
                    "end": 880,
                    "text": "(7)",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 979,
                    "end": 982,
                    "text": "(7)",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1124,
                    "end": 1127,
                    "text": "(1)",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 1269,
                    "end": 1272,
                    "text": "(7)",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1850,
                    "end": 1853,
                    "text": "(9)",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 2064,
                    "end": 2068,
                    "text": "(10)",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 2163,
                    "end": 2167,
                    "text": "(11)",
                    "ref_id": "BIBREF9"
                }
            ],
            "ref_spans": [],
            "section": "LETTER TO THE EDITOR"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Warp-Speed Covid-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships",
            "authors": [
                {
                    "first": "Rjy",
                    "middle": [],
                    "last": "Ho",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Pharm Sci",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.xphs.2020.11.010"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "COVID-19): Current Status and Prospects for Drug and Vaccine Development",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Ita",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Coronavirus Disease",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Arch Med Res",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.arcmed.2020.09.010"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Critical Aspects of Packaging, Storage, Preparation, and Administration of mRNA and Adenovirus-vectored COVID-19 Vaccines for Optimal Efficacy",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Holm",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Poland",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Poland",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Vaccine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.vaccine.2020.12.017"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Addressing the cold reality of mRNA vaccine stability",
            "authors": [
                {
                    "first": "Dja",
                    "middle": [],
                    "last": "Crommelin",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Anchordoquy",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Volkin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Journal of Pharmaceutical Sciences",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.xphs.2020.12.006"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "The Miracle Vaccine for COVID-19? Public Health in Practice, 2020100061. 0188-4409/$ -see front matter. Copyright \u00d3 2021 IMSS",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Badiani",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Ziolkowski",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Pfizer",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.arcmed.2020.12.014"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "India's costeffective COVID-19 vaccine development initiatives",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Chakraborty",
                    "suffix": ""
                },
                {
                    "first": "Agoramoorthy",
                    "middle": [
                        "G"
                    ],
                    "last": "Agoramoorthy",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Vaccine",
            "volume": "38",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.vaccine.2020.10.056"
                ]
            }
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Prevalence and Perception of Needle Stick Injury Among Health Care Professionals at a Tertiary Care Hospital",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Musroor",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Saleem",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Am J Infect Control",
            "volume": "48",
            "issn": "8",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Erdos",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "EBioMedicine",
            "volume": "55",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ebiom.2020.102743"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Effect of microneedle design on pain in human volunteers",
            "authors": [
                {
                    "first": "H",
                    "middle": [
                        "S"
                    ],
                    "last": "Gill",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Clin J Pain",
            "volume": "24",
            "issn": "",
            "pages": "585--594",
            "other_ids": {
                "DOI": [
                    "10.1097/AJP.0b013e31816778f9"
                ]
            }
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Response to: Regarding the Article: Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "None.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflict of Interest"
        }
    ]
}